文献速递心脑血管急症消化、代谢与肾脏急症

睾酮替代治疗的心血管安全性

Cardiovascular Safety of Testosterone-Replacement Therapy.
PubMed 文献 · N Engl J Med · 2023-06-16
一句话结论在患有性腺功能减退且存在或高心血管风险的45-80岁男性中,睾酮替代治疗的心血管安全性不劣于安慰剂(HR 0.96,95%CI 0.78-1.17),但房颤、急性肾损伤和肺栓塞发生率更高。

这项多中心、随机、双盲、安慰剂对照的非劣效性试验纳入5246例45-80岁、有性腺功能减退症状且两次空腹睾酮水平低于300 ng/dl、存在或高心血管风险的男性,随机接受每日经皮1.62%睾酮凝胶(剂量调整至睾酮水平350-750 ng/dl)或安慰剂凝胶。主要心血管安全终点为心血管原因死亡、非致死性心肌梗死或非致死性卒中的复合终点首次发生,非劣效性要求风险比95%CI上限小于1.5。结果主要终点事件在睾酮组发生182例(7.0%),安慰剂组190例(7.3%)(HR 0.96;95%CI 0.78-1.17;非劣效性P<0.001)。睾酮组房颤、急性肾损伤和肺栓塞发生率更高。

要点

  • 在45-80岁有性腺功能减退症状且两次空腹睾酮<300 ng/dl、存在或高心血管风险的男性中,睾酮凝胶组主要心血管事件发生率7.0% vs 安慰剂组7.3%(HR 0.96;95%CI 0.78-1.17;非劣效性P<0.001)。
  • 睾酮组房颤、急性肾损伤和肺栓塞发生率高于安慰剂组。
  • 非劣效性界值为风险比95%CI上限小于1.5。
  • 平均治疗时长21.7±14.1个月,平均随访33.0±12.1个月。
  • 敏感性分析中在停用睾酮或安慰剂后不同时间点删失事件数据,结果相似。

适用人群与场景

  • 45至80岁男性,有性腺功能减退症状,两次空腹睾酮水平低于300 ng/dl,且存在或高心血管疾病风险。

诊断标准与关键阈值

  • 性腺功能减退诊断依据:报告有性腺功能减退症状且两次空腹睾酮水平低于300 ng/dl。
  • 非劣效性界值:风险比95%置信区间上限小于1.5。
  • 睾酮剂量调整目标:维持睾酮水平在350至750 ng/dl之间。

处置流程与药物剂量

  • 每日经皮1.62%睾酮凝胶,剂量调整以维持睾酮水平在350至750 ng/dl之间;对照为安慰剂凝胶。

研究设计与关键结果

  • 多中心、随机、双盲、安慰剂对照非劣效性试验,纳入5246例男性。
  • 主要心血管安全终点(心血管原因死亡、非致死性心肌梗死或非致死性卒中的复合终点首次发生):睾酮组182例(7.0%)vs 安慰剂组190例(7.3%),HR 0.96(95%CI 0.78-1.17),非劣效性P<0.001。
  • 次要心血管终点(心血管原因死亡、非致死性心肌梗死、非致死性卒中或冠状动脉血运重建的复合终点首次发生)及主要复合终点各组分事件发生率在两组间似乎相似。
  • 睾酮组房颤、急性肾损伤和肺栓塞发生率更高。
  • 平均治疗时长21.7±14.1个月,平均随访33.0±12.1个月。
  • 敏感性分析中在停用睾酮或安慰剂后不同时间点删失事件数据,结果相似。

证据类型、等级与局限

  • 证据类型:多中心、随机、双盲、安慰剂对照非劣效性试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于有性腺功能减退症状且两次空腹睾酮<300 ng/dl、存在或高心血管风险的45-80岁男性,睾酮替代治疗的心血管安全性不劣于安慰剂。
  • 使用睾酮替代治疗时需注意房颤、急性肾损伤和肺栓塞发生率更高。

指南或共识出处

  • TRAVERSE试验(ClinicalTrials.gov编号NCT03518034),由AbbVie等资助。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The cardiovascular safety of testosterone-replacement therapy in middle-aged and older men with hypogonadism has not been determined.

METHODS: In a multicenter, randomized, double-blind, placebo-controlled, noninferiority trial, we enrolled 5246 men 45 to 80 years of age who had preexisting or a high risk of cardiovascular disease and who reported symptoms of hypogonadism and had two fasting testosterone levels of less than 300 ng per deciliter. Patients were randomly assigned to receive daily transdermal 1.62% testosterone gel (dose adjusted to maintain testosterone levels between 350 and 750 ng per deciliter) or placebo gel. The primary cardiovascular safety end point was the first occurrence of any component of a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, assessed in a time-to-event analysis. A secondary cardiovascular end point was the first occurrence of any component of the composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization, assessed in a time-to-event analysis. Noninferiority required an upper limit of less than 1.5 for the 95% confidence interval of the hazard ratio among patients receiving at least one dose of testosterone or placebo.

RESULTS: The mean (±SD) duration of treatment was 21.7±14.1 months, and the mean follow-up was 33.0±12.1 months. A primary cardiovascular end-point event occurred in 182 patients (7.0%) in the testosterone group and in 190 patients (7.3%) in the placebo group (hazard ratio, 0.96; 95% confidence interval, 0.78 to 1.17; P<0.001 for noninferiority). Similar findings were observed in sensitivity analyses in which data on events were censored at various times after discontinuation of testosterone or placebo. The incidence of secondary end-point events or of each of the events of the composite primary cardiovascular end point appeared to be similar in the two groups. A higher incidence of atrial fibrillation, of acute kidney injury, and of pulmonary embolism was observed in the testosterone group.

CONCLUSIONS: In men with hypogonadism and preexisting or a high risk of cardiovascular disease, testosterone-replacement therapy was noninferior to placebo with respect to the incidence of major adverse cardiac events. (Funded by AbbVie and others; TRAVERSE ClinicalTrials.gov number, NCT03518034.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023. PMID: 37326322. doi:10.1056/NEJMoa2215025

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。